Cabot Corporation (NYSE: CBT) — FY2022 Form 10-K
Reporting period: Fiscal year ended September 30, 2022. This is a full-year annual report, not a standalone fourth-quarter report. Unless otherwise stated, financial amounts are in millions of U.S. dollars.
Business context
Cabot is a global specialty chemicals and performance materials company. Its two continuing reportable segments are Reinforcement Materials and Performance Chemicals. The company sold its Purification Solutions business on March 1, 2022. China accounted for approximately 25% of FY2022 revenue and approximately 25% of property, plant and equipment at year-end.
Financial performance and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Net sales and operating revenues | $4,321 | $3,409 |
| Gross profit | $885 | $799 |
| Gross margin | 20.5% | 23.4% |
| Income from operations | $389 | $454 |
| Net income attributable to Cabot | $209 | $250 |
| Diluted EPS | $3.62 | $4.34 |
| Cash provided by operating activities | $100 | $257 |
| Capital expenditures | $211 | $195 |
Revenue increased 27%, primarily from $1.1 billion of favorable pricing and product mix, higher volumes and increased energy-center by-product revenue; divestiture and foreign exchange partly offset growth. Gross profit rose, but gross margin declined as cost of sales grew faster than revenue. Net income fell mainly because of a $207 million Purification Solutions sale and impairment charge.
Segment results: Reinforcement Materials revenue was $2,575 and EBIT was $408, versus $1,781 and $329 in FY2021. Performance Chemicals revenue was $1,372 and EBIT was $234, versus $1,148 and $211. Management cited improved pricing and mix in both segments, stronger Reinforcement Materials volumes, and battery-materials demand; higher fixed and utility costs, foreign exchange and weaker fumed metal oxides volumes were offsets.
Balance sheet and funding: At September 30, 2022, cash was $206; current assets were $1,820 and current liabilities $1,105. Total debt was approximately $1,443, including $347 of short-term borrowings and $1,096 of long-term debt. Credit-agreement borrowing availability was $856, and Cabot reported compliance with its leverage covenant. Operating cash flow was pressured by a $431 increase in net working capital, principally receivables and inventory. FY2023 capital spending was forecast at $300–$350.
Cabot issued $400 of 5.0% notes due 2032 and used part of the proceeds to repay $350 of 3.7% notes due in 2022. FY2022 dividends were $1.48 per share ($84 total); share repurchases were $49, excluding employee-tax-related share withholding. The operating tax rate, a non-GAAP measure, was 26% versus 27% in FY2021; the reported effective tax rate was 30% in both years.
Outlook, material items and risks
- For FY2023, management expected Reinforcement Materials EBIT growth from stable volumes and higher pricing in calendar-year customer agreements.
- Performance Chemicals was expected to face weaker specialty-carbons and fumed-metal-oxides demand, particularly in Europe and China, in the first half, with improvement as customer destocking abates and battery-materials and inkjet sales grow.
- Management anticipated a strong U.S. dollar to reduce reported results and higher interest rates to raise costs on floating-rate debt. FY2023 operating tax rate guidance was 26%–28%.
- Growth investments include battery-materials capacity in China, an inkjet production line expected to operate in FY2023, and a specialty-compounds unit in Indonesia expected to be completed in FY2023. The Tianjin conductive-carbon conversion’s first unit was expected to be completed in FY2024.
- Environmental compliance remains a significant cost and execution risk: Cabot spent $80 on environmental capital projects in FY2022 and expected about $92 in FY2023. U.S. air-control installations were estimated at $225–$250 through FY2024, with about $145 incurred by year-end; the Ville Platte compliance date was under discussion for extension to mid-2024.
- Notable exposures include a $39 respirator-liability reserve, whose estimate could change materially, and a disputed foreign VAT assessment with a possible loss range from nil to $41. Aearo’s July 2022 Chapter 11 filing may affect the allocation of respirator claims. Environmental remediation reserves were $4.
- Key broader risks include raw-material and energy volatility, competitive pricing and customer concentration, plant outages and supply-chain disruption, stricter emissions and climate rules, foreign-exchange and interest-rate exposure, cybersecurity, and political, regulatory and operational risks in China. The filing identifies five major tire customers as a material portion of Reinforcement Materials sales.
The company reported a $24 bargain-purchase gain on acquiring the Tianjin carbon-black facility. Auditors issued unqualified opinions on the financial statements and internal control; the respirator-liability estimate was identified as a critical audit matter.
Important facts for investors to verify
- Whether FY2023 segment guidance is tracking, especially the pace of Performance Chemicals demand recovery and Reinforcement Materials pricing.
- Working-capital conversion and operating cash flow after the FY2022 cash tied up in receivables and inventory.
- Debt, commercial-paper balances, floating-rate exposure and available credit as interest rates and capital spending rise.
- Progress, timing and final costs for U.S. emissions controls and planned battery-materials, inkjet and specialty-compounds expansions.
- Developments in the respirator claims and Aearo bankruptcy, as well as the VAT dispute and potential exposure.
- Whether China-related sales, assets and planned battery-materials growth remain resilient to operating restrictions, policy changes and geopolitical risks.